A Phase I Trial to Utilize Systems Biology Approaches to Examine the Safety, Immunogenicity, and 'Omics Response to MVA-BN-Filo and Ad26.ZEBOV Vaccines in Healthy Volunteers

Trial Profile

A Phase I Trial to Utilize Systems Biology Approaches to Examine the Safety, Immunogenicity, and 'Omics Response to MVA-BN-Filo and Ad26.ZEBOV Vaccines in Healthy Volunteers

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 25 Jan 2018

At a glance

  • Drugs Ad26 EBOV vaccine (Primary) ; Modified Vaccinia Ankara Bavarian Nordic Ebola Marburg vaccine (Primary)
  • Indications Ebola virus infections; Marburg virus disease
  • Focus Adverse reactions; Pharmacodynamics
  • Most Recent Events

    • 18 Jan 2018 Planned primary completion date changed from 5 Jan 2018 to 15 Mar 2019.
    • 18 Jan 2018 Status changed from not yet recruiting to active, no longer recruiting.
    • 24 Sep 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top